You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Treating the Hospitalized COVID-19 Patient: Applying the Evolving Evidence to Your Practice

  • Authors: Glen B. Chun, MD; Rachel DeCosta, FNP-C; James H. Finigan, MD; Robert C. Hilton, MD, MEd; Carrie A. Horn, MD; William J. Janssen, MD; Kelly Kuk, PharmD, BCPS, BCIDP; Bart Lambrecht, MD, PhD; and Brandon J. Webb, MD
  • CME / CE Released: 1/20/2023
  • Valid for credit through: 1/20/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    Nurses - 1.50 contact hour(s) (0 contact hours are in the area of pharmacology)

    Pharmacists - 1.50 Knowledge-based ACPE (0.150 CEUs)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

US: hospitalists, pulmonologists, internal medicine, emergency medicine, critical care, infectious disease specialists, registered nurses, NPs and PAs, clinical pharmacists

EU and Global: pulmonologists, critical care, emergency medicine, internal medicine, and infectious disease specialists

This educational program will cover the pathophysiology of COVID-19 and how our understanding of this guides therapeutic decisions. The multidisciplinary faculty panel will discuss communication strategies with patients, American and European guidelines for the in-patient treatment of COVID-19, including supportive therapies and strategies for special populations, as well as management of patients post-hospitalization and patients with long COVID. Lastly, we will discuss clinical trials of new and emerging treatments.

Upon completion of this activity, participants will be able to:

  1. Identify key characteristics of COVID-19 pathophysiology and know the risk factors that are associated with progressive and severe disease.
  2. Employ practical strategies for communication and education for at-risk patients who may become hospitalized patients with COVID-19.
  3. Differentiate clinical strategies based on the stages regarding current guidelines for the patients hospitalized with COVID-19.
  4. Apply evidence-based treatment plans based on current recommended guidelines and best practices for patients hospitalized with COVID-19.
  5. Assess the challenges and impact of comorbidities in the treatment of patients hospitalized with hospitalized COVID-19.
  6. Involve multiple specialists, advanced practitioners, nurses, clinical pharmacists, and others in coordination of patient care regarding diagnosis, treatment, and management of comorbidities.
  7. Evaluate new and emerging therapies for COVID-19 based on the latest efficacy and safety data as evidence evolves from leading clinical trials.
  8. Integrate post-hospitalization factors and plans for overall management strategies for patients hospitalized with COVID-19.


Disclosures

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

Unlabeled and Investigational Usage

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer Statement

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.


Co-Chairs

  • James H. Finigan, MD

    Director, The Respiratory Centers of Excellence
    Medical Director, Lung Cancer Screening Program
    Professor, Division of Pulmonary, Critical Care & Sleep Medicine
    Division of Oncology, Cancer Center
    Department of Medicine
    National Jewish Health
    Denver, Colorado, United States

    Disclosures

    James H. Finigan, MD, has no relevant financial relationships.

  • William J. Janssen, MD

    Section Head, Critical Care Medicine
    Professor of Medicine
    Section of Critical Care Medicine
    Division of Pulmonary, Critical Care & Sleep Medicine
    Department of Medicine
    National Jewish Health
    Denver, Colorado, United States

    Disclosures

    William J. Janssen, MD, has no relevant financial relationships.

Faculty

  • Glen B. Chun, MD

    Clinical Director, Mount Sinai National Jewish Respiratory Institute
    Assistant Professor
    Division of Pulmonary, Critical Care and Sleep Medicine
    Department of Medicine
    New York, New York, United States

    Disclosures

    Glen B. Chun, MD, has no relevant financial relationships.

  • Rachel DeCosta, FNP-C

    Family Nurse Practitioner
    Adult Pulmonary Clinic
    Division of Pulmonary, Critical Care & Sleep Medicine National Jewish Health
    Denver, Colorado, United States

    Disclosures

    Rachel DeCosta, FNP-C, has no relevant financial relationships.

  • Robert C. Hilton, MD, MEd

    Assistant Professor of Medicine
    Thomas Jefferson University
    Philadelphia, Pennsylvania, United States

    Disclosures

    Robert C. Hilton, MD, Med, has no relevant financial relationships.

  • Carrie A. Horn, MD

    Chief Medical Officer
    Chief, Division of Hospital & Internal Medicine
    Associate Professor of Medicine
    National Jewish Health
    Denver, Colorado, United States

    Disclosures

    Carrie A. Horn, MD, has no relevant financial relationships.

  • Kelly Kuk, PharmD, BCPS, BCIDP

    Clinical Pharmacy Specialist
    Infectious Disease
    Saint Joseph Hospital
    Denver, Colorado, United States

    Disclosures

    Kelly Kuk, PharmD, BCPS, BCIDP, has no relevant financial relationships.

  • Bart Lambrecht, MD, PhD

    Professor of Pulmonary Medicine
    ErasmusMC and UGent
    Director, VIB Inflammation Research Center
    Ghent, Belgium

    Disclosures

    Bart Lambrecht, MD, PhD, has no relevant financial relationships.

  • Brandon J. Webb, MD

    Associate Professor
    Division of Infectious Diseases and Clinical Epidemiology
    Intermountain Health
    Murray, Utah, United States

    Disclosures

    Brandon J. Webb, MD, has the following relevant financial relationships:
    Investigator: AbbVie; Gilead; Regeneron; Roche/Genentech.

Planners and Reviewers

Elyce Bowron, MEd, has no relevant financial relationships.
Meghan Brenner, MA, has no relevant financial relationships.
Mandy Comeau has no relevant financial relationships.
James H. Finigan, MD, has no relevant financial relationships.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant financial relationships.
William J. Janssen, MD, has no relevant financial relationships.
Ann Mullen, RN, CNS, CDE, has no relevant financial relationships.
Joshua Solomon, MD, has no relevant financial relationships.


Accreditation Statements

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    For Physicians

  • National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    National Jewish Health designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    European Physicians:
    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at [email protected]

    Contact This Provider

    For Nurses

  • Provider approved by the California Board of Registered Nursing, Provider Number 12724 for 1.5 contact hours.

    Contact This Provider

    For Pharmacists

  • National Jewish Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    ACPE

    National Jewish Health designates this enduring material for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: UAN 0831-0000-22-006-H01-P. Activity Type: Knowledge-based.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 80% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Treating the Hospitalized COVID-19 Patient: Applying the Evolving Evidence to Your Practice

Authors: Glen B. Chun, MD; Rachel DeCosta, FNP-C; James H. Finigan, MD; Robert C. Hilton, MD, MEd; Carrie A. Horn, MD; William J. Janssen, MD; Kelly Kuk, PharmD, BCPS, BCIDP; Bart Lambrecht, MD, PhD; and Brandon J. Webb, MDFaculty and Disclosures

CME / CE Released: 1/20/2023

Valid for credit through: 1/20/2024, 11:59 PM EST

processing....

Assessment Survey

Before you begin, please take this brief survey.

  • Print